Clinical Trial Update: Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) [Phase 2, Phase 3]

View source ↗

Summary

The Sirius study evaluating Ultevursen for retinitis pigmentosa due to USH2A exon 13 mutations (Phase 2/3) was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• Usher Syndrome Type Ii

Drugs mentioned

• Ultevursen

Snippet

Sponsor: Laboratoires Thea | Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-07-12